# Small Molecule Drugs Sector

Canonical URL: https://biopharmsignal.com/sector/small-molecule-drugs

Small Molecule Drugs includes companies developing orally available or otherwise chemically synthesized medicines built from relatively low-molecular-weight compounds. This remains one of the broadest and most commercially important categories in biotech and pharma.

Companies currently grouped under Small Molecule Drugs: 20

## Recent Sector News

- 2026-09-02 20:05 EST — ZNTL — [Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences-0168eeb1) — Source: Zentalis
- 2026-09-02 12:00 EST — INVA — [Innoviva to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/INVA/innoviva-to-participate-in-upcoming-investor-conferences-25a4a00b) — Source: Innoviva
- 2026-09-01 21:15 EST — ZNTL — [Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5-e0f2097c) — Source: Zentalis
- 2026-09-01 20:05 EST — EXEL — [Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September](https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-s-d8eb9815) — Source: Exelixis
- 2026-09-01 11:00 EST — BCRX — [BioCryst to Present at Upcoming Investor Conference](https://biopharmsignal.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conference-2f610d6d) — Source: BioCryst Pharmaceuticals
- 2026-09-01 11:00 EST — ENTA — [Enanta Pharmaceuticals to Participate in September Investor Conferences](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-participate-in-september-investor-conferences-05b832bb) — Source: Enanta Pharmaceuticals
- 2026-09-01 07:00 EST — GSK — [GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data](https://biopharmsignal.com/news/GSK/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positi-66e1968d) — Source: GSK plc
- 2026-09-01 03:04 EST — PMVP — [PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities](https://biopharmsignal.com/news/PMVP/pmv-pharma-announces-pricing-of-oversubscribed-50-million-public-offering-of-sec-34341338) — Source: PMV Pharmaceuticals
- 2026-08-31 20:02 EST — PMVP — [PMV Pharma Announces Proposed Public Offering of Securities](https://biopharmsignal.com/news/PMVP/pmv-pharma-announces-proposed-public-offering-of-securities-510fe622) — Source: PMV Pharmaceuticals
- 2026-08-31 20:01 EST — PMVP — [PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-updated-promising-rezatapopt-monotherapy-interim-o-279c1bba) — Source: PMV Pharmaceuticals
- 2026-08-31 18:30 EST — EXEL — [Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories](https://biopharmsignal.com/news/EXEL/exelixis-announces-update-on-patent-litigation-trial-appeal-with-msn-laboratorie-405d9e66) — Source: Exelixis
- 2026-08-24 07:01 EST — GSK — [Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer](https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-accepted-for-priority-review-by-the-us-fda-for-dmmr-msi-h-l-2c5da49b) — Source: GSK plc
- 2026-08-24 07:00 EST — GSK — [Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B](https://biopharmsignal.com/news/GSK/hibsago-bepirovirsen-approved-in-japan-as-first-and-only-functional-cure-for-chr-a5ecb369) — Source: GSK plc
- 2026-08-17 20:01 EST — ZNTL — [Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-closing-of-underwritten-public-offering-inclu-3693e9c4) — Source: Zentalis
- 2026-08-17 11:00 EST — FULC — [Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies](https://biopharmsignal.com/news/FULC/fulcrum-therapeutics-and-slate-medicines-announce-merger-agreement-to-advance-ne-26be20bb) — Source: Fulcrum Therapeutics
- 2026-08-14 12:00 EST — PMVP — [PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-second-quarter-2026-financial-results-and-corporate--2e87485e) — Source: PMV Pharmaceuticals
- 2026-08-14 02:23 EST — ZNTL — [Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-pricing-of-underwritten-public-offering-4c314e2d) — Source: Zentalis
- 2026-08-13 20:01 EST — ZNTL — [Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-proposed-underwritten-public-offering-8556e470) — Source: Zentalis
- 2026-08-13 12:00 EST — CRIS — [Curis, Inc. Announces Pricing of $5.6 Million Public Offering](https://biopharmsignal.com/news/CRIS/curis-inc-announces-pricing-of-5-6-million-public-offering-0f99cc6a) — Source: Curis Inc
- 2026-08-13 05:00 EST — PHAR — [Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older](https://biopharmsignal.com/news/PHAR/pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-15d022ed) — Source: Pharming Group

## Companies

- [FOLD](https://biopharmsignal.com/company/FOLD) — Amicus Therapeutics
- [AZN](https://biopharmsignal.com/company/AZN) — AstraZeneca PLC
- [BCRX](https://biopharmsignal.com/company/BCRX) — BioCryst Pharmaceuticals
- [CRIS](https://biopharmsignal.com/company/CRIS) — Curis Inc
- [LLY](https://biopharmsignal.com/company/LLY) — Eli Lilly
- [ENTA](https://biopharmsignal.com/company/ENTA) — Enanta Pharmaceuticals
- [EPIX](https://biopharmsignal.com/company/EPIX) — ESSA Pharma
- [EXEL](https://biopharmsignal.com/company/EXEL) — Exelixis
- [FGEN](https://biopharmsignal.com/company/FGEN) — FibroGen
- [FULC](https://biopharmsignal.com/company/FULC) — Fulcrum Therapeutics
- [GSK](https://biopharmsignal.com/company/GSK) — GSK plc
- [INVA](https://biopharmsignal.com/company/INVA) — Innoviva
- [JNJ](https://biopharmsignal.com/company/JNJ) — Johnson & Johnson
- [OCUP](https://biopharmsignal.com/company/OCUP) — Ocuphire
- [PHAR](https://biopharmsignal.com/company/PHAR) — Pharming Group
- [PMVP](https://biopharmsignal.com/company/PMVP) — PMV Pharmaceuticals
- [VTYX](https://biopharmsignal.com/company/VTYX) — Ventyx Biosciences, Inc.
- [VRTX](https://biopharmsignal.com/company/VRTX) — Vertex Pharmaceuticals Incorporated
- [VTRS](https://biopharmsignal.com/company/VTRS) — Viatris Inc.
- [ZNTL](https://biopharmsignal.com/company/ZNTL) — Zentalis